Lumos Pharma Inc. | NLNK - Cash And Equivalent


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview

Lumos Pharma Inc.

Lumos Pharma Inc. reported $44.04M in Cash and Equivalent for its fiscal quarter ending in March of 2023.


Cash And Equivalent Change
Aceragen Inc IDRA:US USD 12.04M 14.75M
Agenus AGEN:US USD 164.82M 13.85M
Bristol-Myers Squibb BMY:US USD 9B 128M
Capricor Therapeutics CAPR:US USD 55.78M 46.17M
Celldex Therapeutics CLDX:US USD 54.12M 24.69M
Eli Lilly LLY:US USD 3.55B 1.48B
Incyte Corp INCY:US USD 2.82B 130.37M
Intrexon XON:US USD 9.74M 4.88M
Lumos Pharma Inc. NLNK:US USD 44.04M 11.97M
Nektar Therapeutics NKTR:US USD 76.96M 11.27M
Prothena PRTA:US USD 686.18M 24.22M
Sarepta Therapeutics SRPT:US USD 871.67M 95.11M
Vascular Biogenics VBLT:US USD 26.09M 8.43M